Is the Ki-67 labelling index ready for clinical use?

editorial Is the Ki-67 labelling index ready for clinical use? Cancer is one of the leading causes of death worldwide. Identification of biomarkers that can detect cancer early, monitor disease progression or serve as a surrogate marker for prognosis and prediction will enable us to personalise medicine and improve care of cancer patients. Up to now, the leading parameters that define treatment recommendations in early breast cancer are estrogen receptor (ER), progesterone receptor, and human epidermal growth factor status. In the last years, global gene expression analysis studies have demonstrated the prime role of proliferation signatures in breast cancer prognosis and prediction of response to therapy [1–3]. This could also be shown in a recent meta-analysis of publicly available BC gene expression studies that revealed that the key biological drivers in nine prognostic signatures were proliferation-related genes, in addition to ER signalling and Her2/neu amplification [4]. Using the information provided by expression data, commercially available multigene assays like the Oncotype DX gene test were developed in which 5 of the 16 genes, used in the text, reflect the proliferative status of the tumour. These specific genes, which include Ki-67, are heavily weighted in the formula used to calculate the test's recurrence score [5]. Two large randomised studies, one led by the Eastern Cooperative Oncology Group called Tailorx study and the MINDACT (microarray in node negative disease may avoid chemotherapy) trial coordinated by the Breast International Group, are assessing the role of different multigene assays in determining the benefit of chemotherapy in addition to endocrine treatment in node-negative hormone-positive tumours. The panel of the St Gallen International Expert Consensus on the primary therapy of early breast cancer recommends the use of proliferation markers (e.g. Ki-67 index and mitosis) and multigene assays when choosing the appropriate systemic treatment in addition to traditional parameters, such as stage, grade, and endocrine status [6]. A search on the Web site of the American Society of Clinical Oncology revealed that the guidelines for use of biological markers in breast cancer do not include Ki-67 in the list of required routine markers [7]. The Ki-67 antigen was originally identified by a German group [8] in the early 1980s, by use of a mouse mAb against a nuclear antigen from a Hodgkin's lymphoma-derived cell line. This non-histone protein was named after the researchers' location, Ki for Kiel University, Germany, with the 67 label referring to the clone number …

[1]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[2]  F. Lacombe,et al.  Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. , 1991, Cytometry.

[3]  M. Fernö,et al.  Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. , 1999, Journal of the National Cancer Institute.

[4]  M. Fernö,et al.  Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. , 2001, Human pathology.

[5]  A. Luini,et al.  A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. , 2003, Journal of the National Cancer Institute.

[6]  Yudong D. He,et al.  A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. , 2005, Cancer research.

[7]  Johannes Gerdes,et al.  Ki‐67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells , 2006, Journal of cellular physiology.

[8]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[9]  G Hüttmann,et al.  Chromophore‐assisted light inactivation of pKi‐67 leads to inhibition of ribosomal RNA synthesis , 2007, Cell proliferation.

[10]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[12]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[13]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[14]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  David Cameron,et al.  Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? , 2009, European journal of cancer.

[16]  A. Di Leo,et al.  Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer , 2009, Breast Cancer Research.

[17]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[18]  T. Osako,et al.  Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis , 2010, Breast cancer.

[19]  M. Piccart-Gebhart,et al.  Value of Ki67 in breast cancer: the debate is still open. , 2010, The Lancet. Oncology.

[20]  M. Dowsett,et al.  Comparative validation of the SP6 antibody to Ki67 in breast cancer , 2010, Journal of Clinical Pathology.

[21]  M. Cazzaniga,et al.  Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.